Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beate Wieseler

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Plos One|April 19, 2014
Impact of inclusion of industry trial results registries as an information source for systematic reviewsRegine Potthast, Volker Vervölgyi, Natalie McGauran, et al.
Biometrical Journal. Biometrische Zeitschrift|July 3, 2015
Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugsGuido Skipka, Beate Wieseler, Thomas Kaiser, et al.
Plos Medicine|October 12, 2013
Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available dataBeate Wieseler, Natalia Wolfram, Natalie McGauran, et al.
BMJ (Clinical Research Ed.)|October 14, 2010
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trialsDirk Eyding, Monika Lelgemann, Ulrich Grouven, et al.
BMJ (Clinical Research Ed.)|July 9, 2020
Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient dataKirsten Janke, Katharina Biester, Dietmar Krause, et al.
BMJ (Clinical Research Ed.)|February 28, 2015
Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reportsMichael Köhler, Susanne Haag, Katharina Biester, et al.
Lancet (London, England)|March 23, 2020
Generating comparative evidence on new drugs and devices before approvalHuseyin Naci, Maximilian Salcher-Konrad, Aaron S Kesselheim, et al.
Health Policy (Amsterdam, Netherlands)|February 24, 2015
European collaboration on relative effectiveness assessments: What is needed to be successful?Sarah Kleijnen, Wil Toenders, Folkert de Groot, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2023
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical TrialsBellinda L King-Kallimanis, Melanie Calvert, David Cella, et al.
BMJ (Clinical Research Ed.)|December 5, 2019
Pathways to independence: towards producing and using trustworthy evidenceRay Moynihan, Lisa Bero, Sue Hill, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Plos One|April 19, 2014
Impact of inclusion of industry trial results registries as an information source for systematic reviewsRegine Potthast, Volker Vervölgyi, Natalie McGauran, et al.
Biometrical Journal. Biometrische Zeitschrift|July 3, 2015
Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugsGuido Skipka, Beate Wieseler, Thomas Kaiser, et al.
Plos Medicine|October 12, 2013
Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available dataBeate Wieseler, Natalia Wolfram, Natalie McGauran, et al.
BMJ (Clinical Research Ed.)|October 14, 2010
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trialsDirk Eyding, Monika Lelgemann, Ulrich Grouven, et al.
BMJ (Clinical Research Ed.)|July 9, 2020
Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient dataKirsten Janke, Katharina Biester, Dietmar Krause, et al.
BMJ (Clinical Research Ed.)|February 28, 2015
Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reportsMichael Köhler, Susanne Haag, Katharina Biester, et al.
Lancet (London, England)|March 23, 2020
Generating comparative evidence on new drugs and devices before approvalHuseyin Naci, Maximilian Salcher-Konrad, Aaron S Kesselheim, et al.
Health Policy (Amsterdam, Netherlands)|February 24, 2015
European collaboration on relative effectiveness assessments: What is needed to be successful?Sarah Kleijnen, Wil Toenders, Folkert de Groot, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2023
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical TrialsBellinda L King-Kallimanis, Melanie Calvert, David Cella, et al.
BMJ (Clinical Research Ed.)|December 5, 2019
Pathways to independence: towards producing and using trustworthy evidenceRay Moynihan, Lisa Bero, Sue Hill, et al.
Pageof 5